Apimeds Pharmaceuticals US, Inc. (APUS) Stock Price

APUSStock
$3.87
Market Cap$5.84M
P/E
PEG Ratio
Div yield
Beta0.63

APUS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-110.15%
Price vs S&P 500 (4W)-21.75%
VGM Score3.68

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
APUSApimeds Pharmaceuticals US, Inc.
F$3.87
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered bee venom-based therapy targeting inflammation and pain associated with osteoarthritis and multiple sclerosis. The company's lead candidate is already marketed in South Korea under the brand name Apitoxin for osteoarthritis treatment, providing clinical validation of the therapeutic approach.